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INTRODUCTION
Enzastaurin (LY317615.HCl), an acyclic bisindolylmaleimide, is a selective orally administered protein kinase Cβ (PKCβ) inhibitor. Although initially developed to selectively inhibit PKCβ at nanomolar concentrations (IC 50 of 6 nmol/L), enzastaurin was demonstrated to also inhibit other PKC isoforms including PKCγ, PKCδ, PKCζ, PKCε, PKCξ, PKCε, PKCδ and PKCα by varying degrees (up to 90% inhibition) and at higher micromolar concentrations [1] . In preclinical studies, enzastaurin suppressed signaling through the AKT pathway, induced apoptosis, and suppressed growth of human colon cancer and glioblastoma xenografts [1] . In addition, enzastaurin inhibited glycogen synthase kinase 3 (GSK3) phosphorylation both in tumor tissues and peripheral blood mononuclear cells (PBMC) from treated mice [1] . It is currently used in phase II trials for the treatment of colon cancer, refractory glioblastoma and diffuse large B cell lymphoma [2, 3] .
The activation of PKC has been demonstrated to be required for natural killer (NK) cell [4, 5] and interleukin 2 (IL-2) activated lymphocytes [6] killing of target cells. Also, PKC activation triggers signaling through the phosphoinositide 3-kinase (PI3K)/AKT and GSK3 pathway [7] . Recently, GSK3 was identified as a crucial regulator of innate inflammatory process, regulating components of the interferon (IFN-γ) signaling pathway in macrophages [8] .
In addition, GSK3 was shown to be a potential regulator of NK cell cytotoxicity and IFN-γ secretion [9] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   4 armed with an array of activating receptors that trigger cytolytic granules and cytokine production. Besides expression of several receptors that mediate natural cytotoxicity, NK cells also express CD16 which mediates antibody-dependent cellular cytotoxicity (ADCC) against IgG-coated target cells [10] [11] [12] [13] . While NK cell activating receptors like NKp30, NKp44, NKp46, and CD16 associate with the transmembrane adaptors CD3δ, FcRγ, or DAP12 that contain a cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM) [14] , NKG2D associates with the adaptor protein DAP10 which contains a cytoplasmic YINM motif [15] [16] [17] [18] [19] . The ligation or antibody dependent cross linking of the ITAM-dependent receptors initiates NK cell signal transduction cascade by phosphorylation of tyrosine residues located within conserved ITAM sequences through Src protein tyrosine kinase (PTK) family [20] . These in turn allows the consequent recruitment and activation of Syk and/or ZAP70 PTK and the transmembrane adaptor proteins, linker for activation of T cells, LAT and LAT2 [20, 21] , further leading to the recruitment and activation of downstream effector molecules such as PI3K [5, 22, 23] , the phospholipases PLCγ1 and PLCγ2 [24] [25] [26] [27] , the guanosine triphosphate-guanosine diphosphate exchange factors Vav2 and Vav3, [28] , the extracellular signal-regulated kinase (ERK) [29] , and finally triggers both cytotoxicity and cytokine production [20] . On the other hand, ligation of DAP10 dependent receptor (NKG2D) directly recruits PI3K and Grb2-Vav1 complex [15] [16] [17] [18] [19] , triggering cytotoxicity but not cytokine production [30, 31] .
Since enzastaurin effectively inhibits phosphorylation of PKC, AKT and GSK3 [1] , all pathways necessary for NK cell activation, we therefore investigated the direct effect of enzastaurin in NK-mediated cytotoxicity (natural and antibody-dependent) and cytokine secretion as well as the influence of enzastaurin on signaling pathways involved in NK cell Page 5 of 39 A c c e p t e d M a n u s c r i p t 5 activity. We observed that enzastaurin 1) inhibits NK cell cytotoxicity (both natural and antibody-dependent), 2) specifically suppresses the expression of NKG2D and CD16 in primary NK cells, 3) impairs perforin release without affecting levels of intracellular perforin expression in NK cells and 4) activates GSK-3β in IL-2-stimulated NK cells by inhibition of GSK-3β phosphorylation.
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MATERIALS AND METHODS

Reagents and monoclonal antibodies
Enzastaurin was purchased from Biozol Diagnostica Vertrieb GmbH (Eching, Germany), TDZD-8 was obtained from Enzo Life Sciences GmbH (Loerrach, Germany), recombinant human IL-2 was from Cell Concepts (Umkirch, Germany). The following phycoerythrinconjugated anti-human monoclonal antibodies (mAbs) were used: CD16, NKp30, NKp44, NKp46, NKG2D, DNAM-1, KIR-KIR2DL2/DL3 and KIR3DL1, all from Miltenyi Biotec (Bergisch Gladbach, Germany), perforin and granzyme B were from Abcam (Cambridge, UK).
Cetuximab (Erbitux) was from Merck Pharma GmbH (Darmstadt, Germany).
Cells
A431, K562 and NK-92 cell lines were obtained from American type culture collection (ATCC; Manassas, VA). NK-92 cell line was grown in X-VIVO TM 10 Medium (Lonza Verviers, Belgium) supplemented with 5% human plasma and 100U/ml recombinant IL-2. K562 cell line was grown in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 20% fetal calf serum (FCS), while A431 cell line was grown in IMDM supplemented with 10% FCS. Media and supplements were from Seromed (Berlin, Germany).
Polyclonal NK cell preparation
Buffy coats from healthy blood donors were obtained from the Frankfurt Red Cross
Blood Bank (Frankfurt, Germany). PBMC were isolated from buffy coats by Ficoll-Hypaque density gradient centrifugation followed by separation using the MACS NK cell isolation kit II 
Cytotoxicity assay and flow cytofluorometric analysis
Cytotoxicity of NK cells was determined by a 4 h coupled luminescent method using the "ACELLA-TOX TM " kit (Cell Technology, Mountain View, CA), as described [32] . K562 and 
Cell cycle analysis
Cell cycle was determined using a commercial kit (BD Biosciences, San Jose, CA)
according to the manufacturer's instructions as described previously [33] .
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A c c e p t e d M a n u s c r i p t Following a 1 h incubation period with peroxidase-conjugated secondary Ab at room temperature visualization was performed by enhanced chemiluminescence using a commercially available kit (Amersham, Liverpool, UK). A c c e p t e d M a n u s c r i p t 
Measurement of IFN-γ production, perforin and granzyme B release
Statistics
Values presented are the mean ± standard error of mean (S.E.M) of at least three experiments. Comparisons between two groups were performed using Student's t-test. P-values lower than 0.05 were considered to be significant.
Ethics Statement
For this study, ethical approval/ethics statement and informed consent is not required (not applicable).
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Effect of enzastaurin on viability of NK cells
We first studied effect of enzastaurin at clinically relevant concentrations [35] (0.625 to 2.5 µM) on viability of NK cells. For this purpose, NK cells were cultured simultaneously for 120 h with IL-2 and enzastaurin. Dead cells were identified by fractional DNA content ("sub-G1
fraction"). NK cells treated with IL-2 alone were used as control. Results reveal enzastaurin to be non-toxic to both primary NK cells and NK-92 cell line in the range of therapeutic concentrations ( Fig. 1) . Also, NK cell and NK-92 cell proliferation were not affected by enzastaurin concentrations up to 2.5 µM (not shown).
Enzastaurin suppresses NK cell cytotoxicity without interfering with IFN-γ production
The role of enzastaurin on NK cell cytotoxicity was next investigated. NK cells were A c c e p t e d M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
Enzastaurin interferes with NK-mediated ADCC
Apart from natural cytotoxicity, primary NK cells also mediate ADCC since they express high amounts of CD16 on their cell surface. We investigated whether enzastaurin has any influence on ADCC. For this purpose, primary NK cells treated simultaneously for 120 h with IL-2 and 2.5 µM enzastaurin, were used in a cytolytic experiment against epidermal growth factor receptor (EGFR)-expressing tumor cell line A431 [36] . The cell line was coated with the EGFR-specific antibody cetuximab before coculture with NK cells. The result obtained show that while A431 cells were resistant to natural cytotoxicity mediated by IL-2-activated NK cells, the cells were sensitive to IL-2-activated NK-mediated ADCC. Enzastaurin however caused 40% inhibition of NK cell-mediated ADCC of A431 cell line (Fig. 2C) .
Enzastaurin down-modulates NK cell activating receptor expression
NK cell cytotoxicity is critically dependent on signaling through its receptors, leading to granule polarization and exocytosis. Accordingly, it is conceivable that enzastaurin might interfere with NK cell receptor expression pattern. To address this, we investigated the surface expression patterns of NK cell triggering receptors CD16, NKp30, NKp44, NKp46, NKG2D and A c c e p t e d M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 DNAM-1, as well as NK cell inhibitory receptors KIR3DL1 and KIR2DL2/DL3 in non-treated and enzastaurin-treated NK cells. A correlation between NK cell cytotoxicity and NK cell receptor expression pattern was observed. The lytic capacity of NK cells treated with enzastaurin was associated with a specific inhibition of CD16 (involved in ADCC) and NKG2D (involved in natural cytotoxicity) surface expression (Fig. 3A) . The surface expression of NKp30, NKp44, NKp46, KIR3DL1 and KIR2DL2/DL3 were not changed (not shown). Enzastaurin also did not suppress the surface expression of triggering and inhibitory receptors in NK cells cultured simultaneously for 18 h with IL-2 and enzastaurin (not shown). Basically NK cell activating or inhibitory receptor expression levels were 2-3 folds higher in NK cells cultured with IL-2 for 120 h than in NK cells cultured with IL-2 for 18 h.
Enzastaurin impairs perforin release by NK cells
The 
Enzastaurin directly suppresses GSK-3β (ser 9 ) phosphorylation
Enzastaurin has been reported to induce apoptosis in several tumors by interfering with signaling through the PI3K/AKT pathway [1, 37, 38] . We investigated by western blot the influence of enzastaurin on AKT activity and its downstream effectors in NK cells. We observed that although enzastaurin did not influence the phosphorylation of AKT, ribosomal protein S6, and the ribosomal p70S6K ( Fig. 4A and B ) it specifically and dose-dependently suppressed GSK-3β phosphorylation in IL-2-activated primary NK cells (Fig. 5A) and NK-92 cell lines ( Results show that enzastaurin does not affect the phosphorylation of ERK1/2 and p38 in both types of NK cells ( Fig. 5C and D) .
TDZD-8 prevents enzastaurin-induced inhibition of NK cell lysis
A previous report indicated that inactivation of GSK-3 using the specific GSK-3β-inhibitor TDZD-8 increased the cytotoxicity of NK cells [9] . We therefore simultaneously treated NK cells with IL-2, TDZD-8 and enzastaurin for 120 h and performed cytolytic experiments using K562 as target cells. Although treatment with TDZD-8 alone did not Page 
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A c c e p t e d M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 significantly influence target cell lysis by NK cells, combined treatment of NK cells with TDZD-8 and enzastaurin prevented the lytic inhibitory role of enzastaurin ( Fig. 6A and B) . Also, combined treatment enhanced granzyme B release (from 79 pg/ml in non-treated NK cells to 142 pg/ml in enzastaurin-treated NK cells), and partially restored perforin release to levels higher than in NK cells treated with enzastaurin alone (from 697 pg/ml to 1002 pg/ml). The inhibition of NKG2D and CD16 expression were however not prevented by the combined treatment (not shown).
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DISCUSSION
Enzastaurin is a selective PKCβ inhibitor that is under clinical investigation as anti-
cancer drug in phase II trials [1] [2] [3] . The PKC family of serine-threonine protein kinases have not only been implicated in the processes that control tumor cell growth, survival, and progression [43] , but also in the processes essential for NK cell function [4-6, 20, 44-46] . PKC activation can trigger signaling through the ras/ERK pathway [47] and/or the PI3K/AKT pathway [7] . PKCα, PKCβ, and PKCε can also directly phosphorylate AKT at Ser 473 , which is essential for AKT activity [48] [49] [50] . Moreover, both PKC [51, 52] and AKT activity [53] can phosphorylate GSK-3β at Ser 9 , indicating an overlap in these signaling pathways. The phosphorylation of GSK-3β has been described to serve as a reliable pharmacodynamic marker for enzastaurin activity [1] .
In this report, we demonstrate for the first time that clinically achievable enzastaurin concentrations activate GSK-3β in human NK cells by specifically suppressing GSK-3β phosphorylation. Interestingly, enzastaurin had no effect on the phosphorylation of cell proliferation-and cell survival-molecules including AKT, S6, and p70S6K. This finding is in line with data showing that PKC may directly phosphorylate GSK-3β without involvement of AKT [54] . In this context, it appears also not to be too much surprising that phosphorylation of p70S6K and its downstream S6 is not modulated after enzastaurin treatment. P70S6K is a substrate of GSK-3β as well as of AKT and sole inhibition GSK-3β may not be sufficient to affect p70S6K signalling as long as AKT remains unaffected.
NK cell proliferation and viability was not affected by enzastaurin treatment. Enzastaurin exerts its antitumoral effects mainly through cytotoxic and antiproliferative activity [55] . In non- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 17 [9] and us remain obscure. However, there is a distinct difference in the experimental procedure applied that may contribute to the varying results. While Aoukaty and Tan [9] treated IL-2-activated NK cells with TDZD-8 for only 30 min in serum free medium, we treated NK cells simultaneously with IL-2 and TDZD-8 for 120 h and in a medium that contained serum.
The activity of enzastaurin has been profiled in tumor cells using in vitro kinase assays [1] . The authors demonstrated that enzastaurin inhibited PKCβ and other PKC isoforms including PKCγ, PKCδ, PKCζ, PKCε, PKCξ, by approximately 90% or more but showed no substantial inhibition of PKCµ and PKCη. PKCε and PKCδ were also inhibited by nearly 50%
while PKCα was inhibited by 77% [1] . Moreover, different PKC isoforms were shown to phosphorylate GSK3 [54, [58] [59] [60] . Therefore, it is conceivable that PKC isoforms other than PKCß are also inhibited by enzastaurin and contribute to impaired NK functions through effects on GSK3.
Also, specific PKC isoenzymes are known to regulate different cellular functions in stimulated lymphocytes: PKCα and PKCζ are involved in the expression of the IL-2 receptor [61, 62] , whereas PKCβ, PKCδ and PKCε are involved in IL-2 synthesis and in the IL-2-mediated proliferation of T cells [63, 64] . In NK cells, the rapid activation of PKC enables them to mediate natural cytotoxicity towards tumor cells [65, 66] , and PKC activation is essential for triggering lysis in IL-2-activated NK cells [6] . PKCζ was also demonstrated to be required for NK cell activation and in vivo control of tumor progression [44] . Some other report described the absolute requirement of PKCζ for ITAM-mediated IFN-γ secretion, but without a marked influence on the release of cytolytic mediators [20] . Specifically, the authors showed using
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A c c e p t e d M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 18 PKCζ-deficient murine NK cells that NKG2D engagement does not influence target cell lysis and that CD16-mediated ADCC was only slightly affected [20] . This means that PKCζ is necessarily required for NKG2D and CD16-mediated lysis. Also, PKCβ deficiency was shown to have no influence on LPS-induced cytokine production in murine bone marrow-derived mast cells [67] . In our study, enzastaurin did not suppress IFN-γ secretion but specifically downregulated the surface expression of NKG2D, an NK activating receptor that is described to trigger cytotoxicity but not cytokine production [30, 31] . Taken together, NKG2D-mediated natural cytotoxicity and CD16-mediated ADCC in NK cells appear to require PKCβ for their cytolytic function. Although we did not study how engagement of NKG2D receptor or CD16
activates PKCβ and/or PI3K/AKT signaling or downstream events, signaling via 2B4 (another NK cell activating receptor) was shown to be mediated by GSK-3 [9] .
Some studies on the effect of other PKC inhibitors on NK cell activity have been reported. While the PKC inhibitors Gö6976, Rottlerin, and Bisindolylmaleimide III were shown to have no effect on NCR (NKp30, NKp44 and NKp46) expression and NK cell-mediated cytotoxicity, Gö6983 induced a remarkable increase of NCR expression and strongly upregulated the death ligands FasL and TRAIL on primary human NK cells, leading to enhanced NK cell lysis of target cells [68] . The authors therefore speculated that NK cell activation by Gö6983 occurs via an unknown mechanism other than PKC inhibition. Furthermore, the PKC inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride was shown to inhibit both natural cytotoxicity and ADCC of human NK cells [45] . Similar to some data in these reports, enzastaurin had no effect on NCR expression but impaired NK cell cytotoxicity.
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In conclusion, we show for the first time that the PKCβ-specific inhibitor enzastaurin suppresses both ADCC and natural cytotoxicity of human NK cells by inhibiting the expression of NKG2D and CD16 as well as impairment of perforin release. In addition, we show that enzastaurin selectively inhibits GSK-3β phosphorylation (known to be involved in NK cell cytotoxicity) without affecting signaling molecules responsible for cell proliferation and survival (AKT, S6, p70S6K). Although enzastaurin plays vital roles in inhibition of tumor-induced angiogenesis, inhibition of tumor cell proliferation, and induces apoptosis in tumor cells, our data suggest that it also has a negative impact on two crucial NK cell-mediated functions, namely natural cytotoxicity and ADCC. This implies that treatment of tumor patients with enzastaurin may impair their NK cell cytotoxic potential. Careful administration and control of patients undergoing enzastaurin therapy is therefore required.
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